Ergoteles’s Outset Medical OM Stock Holding History

Ergoteles’s Portfolio OM Stock Details OM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-697	Closed	-$192K	–	1371
2023 Q1	$192K	Buy	+697	New	+$256K	0.01%	1019

Other funds holding OM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ergoteles's OM Position: Q2 2023 in Review

Ergoteles sold out of Outset Medical (OM) in Q2 2023, closing a stake of 697 shares — an estimated $192K sold.

Ergoteles first reported a position in OM in Q1 2023 and held it in 1 quarter. The position peaked at $192K in Q1 2023. 154 funds tracked by Wall St. Rank hold OM as of Q2 2023.

Ergoteles reported no remaining Outset Medical position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 697 Outset Medical shares in Q2 2023, an estimated $192K.
Ergoteles first reported a position in Outset Medical in Q1 2023 and held it in 1 quarter.
Ergoteles's Outset Medical position peaked at $192K in Q1 2023.
154 funds tracked by Wall St. Rank held Outset Medical as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.